Candela’s Vbeam Prima features two wavelengths
The pulsed-dye laser Vbeam from Candela for treating vascular skin conditions has received an FDA-cleared upgrade.
The Vbeam Prima consists of two wavelengths – 595 nm and 1064 nm – to effectively treat a broad range of skin conditions, including rosacea, spider veins, wrinkles and acne.
“I am most excited about 50 percent greater energy available from this system, thus allowing higher fluences and dramatically larger spot sizes up to a 15 mm beam diameter,” says Eric Bernstein, M.D., director of laser surgery and cosmetic dermatology at the Main Line Center for Laser Surgery in Ardmore, Pennsylvania, an investigational site for the device.
Dr. Bernstein, who has performed hundreds of treatments with the Vbeam Prima, says these benefits not only enable faster treatments, “but in my opinion may offer better treatments as well.”
Dr. Bernstein also points out the two cooling systems. “The existing, highly effective and reliable Dynamic Cooling Device (DCD)administers consistent and predictable skin protection, whereas the new EverCool contact cooling will offer a second option I may use for certain applications,” he says.
Dr. Bernstein tells The Aesthetic Channel that the Vbeam Prima is gentle enough to use on both infants and patients older than 90 years.
“Conditions treated with this type of laser include lower extremity or facial spider veins, port-wine stains, rosacea, aging due to the sun, acne, scars, warts, scars, red striae and psoriasis,” Dr. Bernstein says.
Because the Vbeam Prima is such a versatile tool, the treatment protocol and result time will vary, based on the treatment area and skin condition being treated.
“Treatment sessions can take as little as a couple of minutes,” Dr. Bernstein says. “Cooling minimizes discomfort during therapy and protects the epidermis.”
In a clinical study using Vbeam Prima, “facial redness and rosacea symptoms were dramatically reduced after four treatment sessions,” Dr. Bernstein reports. “This laser is an extremely safe device and its predecessors have a safety profile extending back decades. It is by far one of the safest energy-based devices on the market.”
Dr. Bernstein has received grant funding from Syneron Candela and Zeltiq. He also has received consulting fees from and holds ownership interest in Syneron Candela, and has served on the advisory board for Novoxel, Solta, Syneron Candela and Zeltiq.